Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer

Camilla Qvortrup, Benny Vittrup Jensen, Trine Lembrecht Jørgensen, Dorte Nielsen, Jon Kroll Bjerregaard, Per Pfeiffer

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Results of continuous sunitinib, in combination with cetuximab and irinotecan every other week (SIC) for compassionate use in heavily pre-treated patients with mCRC are presented.
Original languageEnglish
JournalActa Oncologica
Volume49
Issue number6
Pages (from-to)833-836
Number of pages4
ISSN0284-186X
DOIs
Publication statusPublished - 1. Aug 2010

Keywords

  • Administration, Oral
  • Adult
  • Aged
  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Camptothecin
  • Colorectal Neoplasms
  • Denmark
  • Drug Administration Schedule
  • Female
  • Humans
  • Indoles
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Organoplatinum Compounds
  • Pyrroles
  • Receptor Protein-Tyrosine Kinases
  • Retrospective Studies
  • Treatment Outcome

Fingerprint Dive into the research topics of 'Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer'. Together they form a unique fingerprint.

Cite this